Shares of Charles River Laboratories (NYSE: CRL ) have had a difficult year, losing about a quarter of their value and missing out on a meaningful bull market. The drug testing company has faced pressure from a more difficult funding environment Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving ...